The all Hub website uses a third-party service provided by Google that dynamically translates web content. Translations are machine generated, so may not be an exact or complete translation, and the all Hub cannot guarantee the accuracy of translated content. The all and its employees will not be liable for any direct, indirect, or consequential damages (even if foreseeable) resulting from use of the Google Translate feature. For further support with Google Translate, visit Google Translate Help.
The ALL Hub is an independent medical education platform, sponsored by Jazz Pharmaceuticals, Amgen, and Pfizer and supported through an educational grant from the Hippocrate Conference Institute, an association of the Servier Group. The funders are allowed no direct influence on our content. The levels of sponsorship listed are reflective of the amount of funding given. View funders.
Now you can support HCPs in making informed decisions for their patients
Your contribution helps us continuously deliver expertly curated content to HCPs worldwide. You will also have the opportunity to make a content suggestion for consideration and receive updates on the impact contributions are making to our content.
Find out more
Create an account and access these new features:
Bookmark content to read later
Select your specific areas of interest
View all content recommended for you
How has targeted therapy impacted the prognosis for patients with a high disease burden in ALL?
Featured:
Elias JabbourDuring the European School of Haematology (ESH) 2nd Translational Research Conference: Acute Lymphoblastic Leukaemia, the ALL Hub spoke to Elias Jabbour, MD Anderson Cancer Center, Houston, US. We asked, How has targeted therapy impacted the prognosis for patients with a high disease burden in ALL?
How has targeted therapy impacted the prognosis for patients with a high disease burden in ALL?
In this video, Jabbour discusses the impact of targeted therapies for adult patients with ALL, including tyrosine kinase inhibitors, monoclonal and conjugated antibodies, bispecific engagers, and chimeric antigen receptor (CAR) T cells. He believes targeted therapies significantly improve the outcomes of patients with high disease burden.